Business Wire

Octave Presents Clinical Validation Results of its Multivariate Blood-based Multiple Sclerosis Disease Activity Biomarker Test at ACTRIMS Forum 2022

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave, the developer of a fully-integrated Precision Care Solution built to deliver comprehensive insights that bring scientific clarity to multiple sclerosis (MS ...
Financial Times

Octave® Bioscience, Inc. Announces Publication of Clinical Validation Study Results of its Novel, Multivariate Multiple Sclerosis Disease Activity (MSDA) Blood Test

MENLO PARK, Calif.--(BUSINESS WIRE)--Aug. 30, 2023-- Octave ® Bioscience, Inc., a leading precision care company focused on delivering a new standard of care for multiple sclerosis (MS) and other ...
markets.financialcontent

Octave Presents Clinical Validation Results of its Multivariate Blood-based Multiple Sclerosis Disease Activity Biomarker Test at ACTRIMS Forum 2022

Octave Presents Clinical Validation Results of its Multivariate Blood-based Multiple Sclerosis Disease Activity Biomarker Test at ACTRIMS Forum 2022 ...
markets.financialcontent

Octave Presents Clinical Validation Results of its Multivariate Blood-based Multiple Sclerosis Disease Activity Biomarker Test at ACTRIMS Forum 2022

Octave, the developer of a fully-integrated Precision Care Solution built to deliver comprehensive insights that bring scientific clarity to multiple sclerosis (MS), today announced the presentation ...
streetinsider

Octave Presents Clinical Validation Results of its Multivariate Blood-based Multiple Sclerosis Disease Activity Biomarker Test at ACTRIMS Forum 2022

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. Data shows multivariate test is highly associated with multiple Disease Activity ...